Capricor $CAPR -68% after hours. FDA rejected deramiocel for Duchenne.
It was telegraphed:
- July: FDA panel voted 9-3 that the data didn't show efficacy
- FDA staff flagged that Capricor changed its analysis after the trial ended
I guess lesson is when the analysis plan moves after unblinding, so does your stock.
2
705
Replying to @TraderPamplona
I was in that camp until you posted the chart of the previous drawdowns. Your target was inline with that.
Well done on the call 👍
1
47
On the weekend the FDA rejected $SMMT drug. PFS win, but OS missed: HR 0.79, p=0.057. Not enough.
48 hours later Sellas $SLS hits OS outright in AML:
24.0 vs 14.7 months median survival
HR 0.59, p=0.035
The catch: 126 patients, 80 deaths. A small trial, but on the right endpoint.
The FDA just told everyone which endpoint it pays for. Sellas plans its BLA for 1H 2027
1
332
Quebecor’s $QBR.B.TO offer is worth about C$19.45 per share, valuing Telus $T.TO at around C$31 billion ($21.7 billion). That would be a 60% premium to Friday’s closing share price.
216
CANACCORD $CF.TO ENTERS INTO AGREEMENT TO BE TAKEN PRIVATE BY CHAIRMAN AND CEO DAN DAVIAU
Shareholders to receive aggregate consideration of $15.27 per common share comprised of $7.45, plus proceeds of £4.15








